# Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

> **NCT00002153** · PHASE1 · COMPLETED · sponsor: **DEKK-TEC, Inc.** · enrollment: 25 (—)

## Conditions studied

- Sarcoma, Kaposi
- HIV Infections
- Lymphoproliferative Disorders

## Interventions

- **DRUG:** A-007

## Key facts

- **NCT ID:** NCT00002153
- **Lead sponsor:** DEKK-TEC, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 25 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002153, "Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00002153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*